Loading clinical trials...

Factors Associated With Mortality in Streptococcal Anginosus Bacteremia | Clinical Trials | Clareo Health

RECRUITING

Factors Associated With Mortality in Streptococcal Anginosus Bacteremia

NCT07343167•University Hospital, Strasbourg, France

Summary

Streptococcal anginosus infections (S. constellatus, S. anginosus, and S. intermedius) are characterized by their severity, linked to high mortality and frequent infectious complications. Several studies in the literature highlight this severity, with mortality rates estimated at around 15%. The aim of this research is to identify the factors associated with mortality in Streptococcal anginosus bacteremia.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Major subject (≥18 years old)
•Hospitalized between January 1, 2019, and December 31, 2024, in one of the participating centers
•Having presented during the study period at least one positive blood culture for Streptococcus anginosus, Streptococcus constellatus, or Streptococcus intermedius in a laboratory at a participating center

Exclusion Criteria

•Refusal to participate in the study

Locations (1)

Centre de référence des maladies vectorielles à tiques, CNR Borrelia - CHU de Strasbourg - France

Strasbourg, France

Key Dates

Start Date

September 8, 2025

Primary Completion Date

March 1, 2027

Completion Date

March 8, 2027

Last Updated

January 15, 2026

Enrollment

400

ESTIMATED participants

Conditions

Streptococcal Infections

Contacts

Victor GERBER, MD

CONTACT

33 3 68 85 37 97 victor.gerber@chru-strasbourg.fr

Group A Streptococcus Saliva Study

NCT06473506

Group A Streptococcal Infections

View study

COMPLETEDPHASE3

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

NCT04841369

Pneumococcal InfectionsStreptococcal Infections+1 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 15, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Factors Associated With Mortality in Streptococcal Anginosus Bacteremia

Inclusion Criteria

Exclusion Criteria

Group A Streptococcus Saliva Study

Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)

A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A BOOSTER DOSE OF A GROUP B STREPTOCOCCUS 6 VALENT POLYSACCHARIDE CONJUGATE VACCINE (GBS6) IN HEALTHY ADULTS

Rapid Strep Testing in Children With Recent Streptococcal Pharyngitis

Magnitude of the Antibody Response to and Safety of a GBS Trivalent Vaccine in HIV Positive and HIV Negative Pregnant Women and Their Offsprings